{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:49Z","timestamp":1793176789410,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2024JH2\/102600272"],"award-info":[{"award-number":["2024JH2\/102600272"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacl.2026.07.040","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:46:58Z","timestamp":1786117618000},"page":"2277-2287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients\u00a0with\u00a0ultrahigh-risk ASCVD"],"prefix":"10.1016","volume":"20","author":[{"given":"Xiaoping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6147-398X","authenticated-orcid":false,"given":"Na","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.jacl.2026.07.040_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"10384","key":"10.1016\/j.jacl.2026.07.040_bib2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"issue":"45","key":"10.1016\/j.jacl.2026.07.040_bib3","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1093\/eurheartj\/ehad446","article-title":"Eliminating atherosclerotic cardiovascular disease residual risk","volume":"44","author":"Makover","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.040_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1273042","article-title":"Small dense low-density lipoprotein as biomarker for atherosclerotic diseases","volume":"2017","author":"Ivanova","year":"2017","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"10.1016\/j.jacl.2026.07.040_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019140","article-title":"Small dense low-density lipoprotein cholesterol is the most atherogenic lipoprotein parameter in the prospective framingham offspring study","volume":"10","author":"Ikezaki","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.07.040_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.804214","article-title":"Small, dense low-density lipoprotein-cholesterol and atherosclerosis: relationship and therapeutic strategies","volume":"8","author":"Jin","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2026.07.040_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/jdi.14398","article-title":"Clinical significance of small dense low-density lipoprotein cholesterol measurement in type 2 diabetes","volume":"16","author":"Hirano","year":"2025","journal-title":"J Diabetes Investig"},{"issue":"16","key":"10.1016\/j.jacl.2026.07.040_bib8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jacl.2026.07.040_bib9","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.040_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.jacl.2026.07.040_bib11","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.jacl.2026.07.040_bib12","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.117.029095","article-title":"Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial)","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2026.07.040_bib13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jcmg.2021.11.014","article-title":"Determinants of plaque progression despite very low low-density lipoprotein-cholesterol levels with the PCSK9 inhibitor, evolocumab","volume":"15","author":"Honda","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.jacl.2026.07.040_bib14","first-page":"237","article-title":"Chinese guidelines for the management of dyslipidemia (2023)","volume":"38","author":"Wang","year":"2023","journal-title":"Zhongguo Xun Huan Za Zhi"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.040_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1309\/AJCPLHJBGG9L3ILS","article-title":"Estimation of plasma small dense LDL cholesterol from classic lipid measures","volume":"136","author":"Srisawasdi","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1016\/j.jacl.2026.07.040_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/clinchem\/hvab048","article-title":"A new equation based on the standard lipid panel for calculating small dense low-density lipoprotein-cholesterol and its use as a risk-enhancer test","volume":"67","author":"Sampson","year":"2021","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.jacl.2026.07.040_bib17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0735-1097(90)90282-T","article-title":"Quantification of coronary artery calcium using ultrafast computed tomography","volume":"15","author":"Agatston","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.07.040_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.atherosclerosis.2019.05.012","article-title":"A guide for gensini score calculation","volume":"287","author":"Rampidis","year":"2019","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jacl.2026.07.040_bib19","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1016\/S2589-7500(22)00022-X","article-title":"Deep learning-enabled coronary CT angiography for plaque and stenosis quantification and cardiac risk prediction: an international multicentre study","volume":"4","author":"Lin","year":"2022","journal-title":"Lancet Digit Health"},{"issue":"7","key":"10.1016\/j.jacl.2026.07.040_bib20","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"issue":"20","key":"10.1016\/j.jacl.2026.07.040_bib21","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2026.07.040_bib22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1053\/meta.2002.34695","article-title":"Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B","volume":"51","author":"Ohmura","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2026.07.040_bib23","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jacasi.2025.04.015","article-title":"Discordance of small dense LDL cholesterol beyond LDL cholesterol or non-HDL cholesterol and carotid plaque","volume":"5","author":"Wang","year":"2025","journal-title":"JACC Asia"},{"issue":"11","key":"10.1016\/j.jacl.2026.07.040_bib24","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.07.040_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pathol.2018.11.006","article-title":"Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment","volume":"51","author":"Carr","year":"2019","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.jacl.2026.07.040_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.040_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117312","article-title":"Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook","volume":"383","author":"Raja","year":"2023","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.jacl.2026.07.040_bib28","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/CIRCRESAHA.120.316697","article-title":"For non-HDL cholesterol, \u201cLower Is Better\u201d but \u201cLower for Longer\u201d may be best","volume":"126","author":"Nayor","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2026.07.040_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7967380","article-title":"Correlation between cholesterol, triglycerides, calculated, and measured lipoproteins: whether calculated small density lipoprotein fraction predicts cardiovascular risks","volume":"2017","author":"Khan","year":"2017","journal-title":"J Lipids"},{"issue":"6","key":"10.1016\/j.jacl.2026.07.040_bib30","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/clinchem\/hvae061","article-title":"Impact of direct measurement of small dense low-density lipoprotein cholesterol for long-term secondary prevention in patients with stable coronary artery disease","volume":"70","author":"Koba","year":"2024","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.jacl.2026.07.040_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.116.025080","article-title":"Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism","volume":"135","author":"Watts","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2026.07.040_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11883-021-00913-8","article-title":"Preventing diabetes and atherosclerosis in the cardiometabolic syndrome","volume":"23","author":"Ahmad","year":"2021","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"10.1016\/j.jacl.2026.07.040_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0735-1097(88)90400-7","article-title":"Change in diameter of coronary artery segments adjacent to stenosis after percutaneous transluminal coronary angioplasty: failure of percent diameter stenosis measurement to reflect morphologic changes induced by balloon dilation","volume":"12","author":"Beatt","year":"1988","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.07.040_bib34","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s002700010040","article-title":"Instability of reference diameter in the evaluation of stenosis after coronary angioplasty: percent diameter stenosis overestimates dilative effects due to reference diameter reduction","volume":"23","author":"Hirami","year":"2000","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9","key":"10.1016\/j.jacl.2026.07.040_bib35","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jacl.2026.07.040_bib36","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ehjci\/jez022","article-title":"Differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: the progression of AtheRosclerotic PlAque DetermIned by computed TomoGraphic angiography imaging (PARADIGM) study","volume":"20","author":"Lee","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.jacl.2026.07.040_bib37","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/0735-1097(88)90226-4","article-title":"Visual estimates of percent diameter coronary stenosis: \u201cA Battered Gold Standard\u201d","volume":"11","author":"Marcus","year":"1988","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:27:56Z","timestamp":1793176076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1933287426004770"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.040","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients\u00a0with\u00a0ultrahigh-risk ASCVD","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}